TruNativ closes $30 million primary-and-secondary Series B with OrbiMed
The nutrition company will expand distribution, develop products and grow its ingredients business.
TruNativ announced a $30 million Series B transaction with OrbiMed on June 16. The deal combines new investment into the company with secondary share sales by early shareholders; the primary allocation was not disclosed.
The Mumbai nutrition business plans to expand distribution, broaden its product range and establish a research and innovation centre. It will also grow its ingredients business serving other consumer brands, alongside its household protein, fibre and sugar-alternative products.
Use of funds
Expand retail distribution
Develop nutrition products and R&D centre
Grow ingredients business